All data are based on the daily closing price as of May 12, 2026
t
Tanvex BioPharma
6541.TW
1.25 USD
-0.02
-1.57%
Overview
Last close
1.25 usd
Market cap
330.10M usd
52 week high
2.50 usd
52 week low
1.24 usd
Target price
1.66 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
25.9598
Price/Book Value
1.8281
Enterprise Value
352.33M usd
EV/Revenue
27.7048
EV/EBITDA
-9.0582
Key financials
Revenue TTM
12.72M usd
Gross Profit TTM
-13.98M usd
EBITDA TTM
-39.50M usd
Earnings per Share
-0.19 usd
Dividend
N/A usd
Total assets
253.63M usd
Net debt
22.29M usd
About
Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicines. The company was founded in 2011 and is headquartered in George Town, the Cayman Islands.